Related Experiment Videos
Adjuvant Therapy for Melanoma.
Aya Agha1, Ahmad A Tarhini2,3
1University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA.
Current Oncology Reports
|April 19, 2017
Summary
Systemic adjuvant therapy for high-risk melanoma aims to eliminate micrometastatic disease. High-dose interferon-alfa (HDI) improved overall survival in some trials, while newer agents like ipilimumab show promise but with toxicities.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Adjuvant therapy is crucial for surgically resected melanoma at high risk of recurrence.
- Interferon-alfa (IFNα) has been extensively studied, with high-dose (HDI) regimens showing survival benefits in some trials.
- Newer immunotherapies like ipilimumab offer improved survival but carry significant toxicities.
Purpose of the Study:
- To review the efficacy and toxicity of systemic adjuvant therapies for high-risk cutaneous melanoma.
- To compare outcomes of interferon-alfa based regimens with newer agents such as ipilimumab and anti-PD-1 antibodies.
Main Methods:
- Review of randomized controlled trials (RCTs) evaluating adjuvant therapies for melanoma.
- Analysis of relapse-free survival (RFS) and overall survival (OS) data.
- Comparison of hazard ratios (HR) for different treatment regimens and agents.
Main Results:
- HDI regimens demonstrated improvements in RFS and OS in specific trials.
- Pegylated interferon-alfa (peg-IFN) improved RFS but not OS.
- Ipilimumab significantly improved RFS and OS in stage III melanoma but with notable toxicities.
Conclusions:
- Adjuvant therapy remains critical for high-risk melanoma patients.
- While HDI has shown benefits, newer immunotherapies like ipilimumab and anti-PD-1 antibodies represent the future direction.
- Ongoing trials are essential to optimize treatment strategies and manage toxicities for improved melanoma patient outcomes.